Andelyn Biosciences Partners with Jaguar Gene Therapy
Andelyn Biosciences, a dedicated cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has joined forces with Jaguar Gene Therapy. This collaboration aims to facilitate late-stage Process Performance Qualification (PPQ) manufacturing of JAG201, a cutting-edge gene therapy specifically designed to address a monogenic cause of autism spectrum disorder known as Phelan-McDermid Syndrome.
Understanding Phelan-McDermid Syndrome
Phelan-McDermid Syndrome is primarily associated with SHANK3 haploinsufficiency, leading to profound neurobehavioral, social, and cognitive challenges. Individuals affected by this condition struggle with developmental milestones, often requiring constant care and support. The existing management strategies mainly focus on symptomatic relief rather than addressing the root causes of the disorder, leaving a glaring gap in effective treatments.
The Role of JAG201
JAG201 is engineered as a gene replacement therapy that aims to restore normal SHANK3 function in neurons by using the AAV9 viral vector. This innovative approach targets the neurons within the central nervous system, providing the necessary genetic material to enhance synaptic functions that are crucial for learning and memory. The ultimate goal of JAG201 is to improve the overall cognitive abilities and social interactions of individuals with Phelan-McDermid Syndrome.
Expertise and Capabilities of Andelyn
Andelyn's extensive experience in AAV vector manufacturing and production under Good Manufacturing Practices (GMP) ensures that they are well-equipped to support the manufacturing needs for JAG201. With their advanced technologies and quality systems in place, Andelyn is poised to play a critical role in the acceleration of gene therapies, particularly for patients in need of effective treatment options.
Shared Vision for Gene Therapies
Matt Niloff, Chief Commercial Officer at Andelyn, articulated the partnership's significance, stating, "This collaboration exemplifies our mutual commitment to delivering innovative and safe gene therapies to patients who currently have limited options. Our mission at Andelyn is to optimize the path to commercial readiness for treatments like JAG201, and we are excited to support Jaguar in this important work.”
Rob Mancino, Senior Vice President of Technical Operations at Jaguar Gene Therapy, echoed these sentiments, highlighting the importance of reliable manufacturing processes that maintain purity and efficacy: "Our partnership with Andelyn underlines our dedication to advancing gene therapies and ensuring the highest quality standards for our patients.”
About Andelyn Biosciences
Andelyn Biosciences is recognized for its exemplary contributions in the realm of cell and gene therapy. With over two decades of experience, Andelyn has supported more than 450 clinical batches across 75 clinical trials. Their impressive capabilities include cGMP manufacturing for both suspension and adherent processes, coupled with robust quality systems and regulatory compliance, establishing them as a leader in the industry.
About Jaguar Gene Therapy
Jaguar Gene Therapy is committed to developing transformative gene therapies for severe genetic disorders. They focus not only on Phelan-McDermid Syndrome but also on other significant conditions like Type 1 galactosemia and Type 1 diabetes. With a strong team and a well-defined pipeline, Jaguar is making strides in the field of gene therapy, ensuring that effective treatments are within reach for those affected by these challenging diseases.
Frequently Asked Questions
What is the focus of the partnership between Andelyn and Jaguar?
The partnership focuses on the late-stage manufacturing of JAG201, a gene therapy aimed at treating Phelan-McDermid Syndrome.
What is Phelan-McDermid Syndrome?
Phelan-McDermid Syndrome is caused by SHANK3 haploinsufficiency, leading to severe cognitive, social, and behavioral challenges.
What role does JAG201 play in therapy?
JAG201 delivers functional SHANK3 minigenes to targeted neurons, aiming to restore normal synaptic function and improve cognitive abilities.
How does Andelyn support gene therapy development?
Andelyn leverages its extensive expertise in AAV manufacturing, ensuring high-quality production that meets regulatory standards for gene therapies.
What other conditions does Jaguar Gene Therapy address?
Besides Phelan-McDermid Syndrome, Jaguar is also working on therapies for Type 1 galactosemia and Type 1 diabetes.
